stockportfolio.pro
Stocks / CERS vs PRME
CERS vs PRME
Cerus Corporation and Prime Medicine, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Cerus Corporation (CERS) | Prime Medicine, Inc. (PRME) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $206.13M | $4.63M |
| Net income (latest FY) | $-15.63M | $-201.14M |
| Revenue growth (5y CAGR) | 12.5% | -2.3% |
| Net margin | -7.6% | -4342.4% |
| Return on equity | -24.3% | -166.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CERS — free Open PRME — freeFrequently asked questions
Which is bigger, CERS or PRME?
Cerus Corporation is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, CERS or PRME?
Over the last five fiscal years, Cerus Corporation grew revenue faster — 12.5%/yr versus -2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.